TCRβV-Binding Multifunctional Molecules for Localized T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecules targeting the CD3 epsilon subunit of the T cell receptor for cancer immunotherapy can cause T cell dysfunction, immunosuppressive effects, and cytokine storms, posing risks such as neurotoxicity.
Innovation Solution
A multifunctional molecule comprising a tumor-associated antigen binding moiety, a cytokine molecule, and a TCRβV-binding moiety covalently linked through a dimerization module, allowing selective T cell activation and cytokine release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD3e monoclonal antibody is used to redirect T cells for cancer immunotherapy, then T cell activation is achieved, but T cell dysfunction and immunosuppressive effects occur
Solution Approach 1:
The patent applies local quality by using a multifunctional molecule with distinct functional domains: a TCRβV-binding moiety for selective T cell recognition, a tumor-associated antigen binding moiety for targeted tumor cell binding, and a cytokine molecule for localized immunomodulation. This spatial organization of different functions within a single molecule enables precise control over T cell activation at the tumor site while avoiding systemic immunosuppression.
Solution Approach 2:
The invention segments the therapeutic function into multiple independent modules: (1) TCRβV-binding moiety for T cell engagement, (2) tumor-associated antigen binding moiety for tumor targeting, and (3) cytokine molecule for immune modulation. These segmented functional units are covalently linked to create a multifunctional molecule that delivers each function independently and synergistically, improving therapeutic reliability while reducing harmful side effects.
2Productivity
If anti-CD3e monoclonal antibody binds to all T cells, then massive T cell activation occurs, but cytokine storm and neurotoxicity are caused
Solution Approach 1:
The multifunctional molecule achieves localized T cell activation by simultaneously binding to TCRβV on T cells and tumor-associated antigens on tumor cells. The cytokine molecule is positioned to act locally at the immunological synapse between T cells and tumor cells, producing high concentrations of immunomodulatory cytokines only where needed. This local action achieves productive T cell activation without triggering systemic cytokine storm or neurotoxicity.
Solution Approach 2:
The tumor-associated antigen binding moiety acts as an intermediary that anchors the multifunctional molecule to tumor cells, while the TCRβV-binding moiety engages T cells. This dual-binding mechanism creates a bridge that mediates selective T cell activation only at tumor sites. The cytokine molecule serves as a secondary intermediary that modulates the T cell response locally, preventing uncontrolled systemic activation and associated harmful effects.
3Object-affected harmful factors
If low dose anti-CD3e monoclonal antibody is used, then T cell activation is reduced, but immunosuppressive effects are exerted
Solution Approach 1:
The patent segments the therapeutic action into targeted tumor-specific activation and localized cytokine-mediated immunomodulation. The tumor-associated antigen binding moiety ensures that T cell activation occurs only at tumor sites, while the cytokine molecule provides localized immune support. This segmentation allows effective T cell activation against tumors without triggering systemic immunosuppression that occurs with low-dose anti-CD3e therapy.
Solution Approach 2:
The invention extracts the tumor-targeting function from the general T cell activation mechanism by introducing a tumor-associated antigen binding moiety. This extraction allows the TCRβV-binding moiety to activate T cells selectively only when bound to tumor cells expressing the target antigen, rather than activating all T cells as anti-CD3e antibodies do. The cytokine molecule is extracted and positioned to provide localized immunomodulation, preventing systemic immunosuppression.
Data Source
AI summary
Provides herein are multifunctional molecules comprising T cell receptor variable beta-binding moieties and cytokines, and methods of treating conditions or diseases in a subject using the same.